Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1.
By A. Koh, A. Molinaro, M. Ståhlman, M. Khan, C. Schmidt, L. Mannerås-Holm, Hao Wu, A. Carreras, Heeyoon Jeong, Louise E Olofsson and 8 more. Cell, 2018
684 citations recorded by the source corpus.
Interactions between the gut microbiota, diet, and the host potentially contribute to the development of metabolic diseases. Here, we identify imidazole propionate as a microbially produced histidine-derived metabolite that is present at higher concentrations in subjects with versus without type 2 diabetes. We show that imidazole propionate is produced from histidine in a gut simulator at higher concentrations when using fecal microbiota from subjects with versus without type 2 diabetes and that it impairs glucose tolerance when administered to mice. We further show that imidazole propionate impairs insulin signaling at the level of insulin receptor substrate through the activation of p38γ MAPK, which promotes p62 phosphorylation and, subsequently, activation of mechanistic target of rapamycin complex 1 (mTORC1). We also demonstrate increased activation of p62 and mTORC1 in liver from subjects with type 2 diabetes. Our findings indicate that the microbial metabolite imidazole propionate may contribute to the pathogenesis of type 2 diabetes.
Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/ee815d5c2efb7e23a76e232ef353bf1e2714b65d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Gut microbiota-derived metabolites as central regulators in metabolic disorders (2020, background): “33 In the liver, IMP appeared to affect the insulin signalling pathway via mammalian target of rapamycin complex 1 (mTORC1).”